CD160 and neoplasm: These findings further suggest that combining ICBs with concomitant chemotherapy that specifically block the ICs that are upregulated by chemotherapies which include: PD-1, A2aR, CTLA-4, KLRG-1, PD-L1, PD-L2 and CD160 would represent attractive targets in the tumour microenvironment.